{
    "clinical_study": {
        "@rank": "102636", 
        "arm_group": [
            {
                "arm_group_label": "Healthy Control", 
                "arm_group_type": "No Intervention", 
                "description": "A group of healthy control without any history suggestive of perinatal asphyxia or other diseases, are enrolled to compare different laboratory measurements"
            }, 
            {
                "arm_group_label": "Hypothermia Group", 
                "arm_group_type": "No Intervention", 
                "description": "HIE infants who will not receive melatonin and only receive routine cooling protocol."
            }, 
            {
                "arm_group_label": "Melatonin/ hypothermia group", 
                "arm_group_type": "Experimental", 
                "description": "HIE infants who will receive melatonin in addition to the routine cooling protocol"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to examine the effect of combining melatonin to whole body cooling\n      on the brain injury and outcome of neonates following perinatal asphyxia."
        }, 
        "brief_title": "Melatonin for Neuroprotection Following Perinatal Asphyxia", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Perinatal Asphyxia", 
        "condition_browse": {
            "mesh_term": "Asphyxia"
        }, 
        "detailed_description": {
            "textblock": "This is a prospective study on 30 neonates with moderate to moderately to severe hypoxic\n      ischemic encephalopathy (HIE) . HIE infants are randomized into two groups: Whole body\n      cooling group  (N = 15; receive 72 hours of whole body hypothermia) and melatonin/\n      hypothermia group (N = 15; receive hypothermia and 5 daily enteral doses of melatonin 10\n      mg/kg).  Serum melatonin, plasma superoxide dismutase (SOD),and serum nitric oxide (NO) are\n      measured at enrollment and after 2 weeks for the two  HIE groups. The HIE groups underwent\n      electroencephalography at enrollment and at 2 to 3 weeks. Brain MRI was performed after 2\n      weeks of life. Neurologic evaluations and Denver Developmental Screening Test II assessments\n      were performed at 6 months. A group of healthy newborns will be used as a control for\n      baseline labs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Inborn infants at term gestation (38-42 weeks)\n\n          -  Apgar scores \u2264 3 at 5 minutes and/or delayed first breath (>5 minutes after birth)\n\n          -  Profound metabolic or mixed acidosis with serum bicarbonate levels of <12 mmol/L in\n             initial blood gas analyses\n\n          -  Evidence of moderate or moderate to severe encephalopathy, such as lethargy,\n             seizures, abnormal reflexes, or hypotonia, in the immediate neonatal period\n\n        Exclusion Criteria:\n\n          -  Twin gestation\n\n          -  Maternal neuro-endocrinal disturbances including diabetes mellitus\n\n          -  Chorioamnionitis or congenital infections\n\n          -  Low birth weight less than 2.5 kg\n\n          -  Congenital malformations of the central nervous system or gastrointestinal anomalies\n\n          -  Chromosomal abnormalities\n\n          -  After 6 hours of birth.\n\n          -  Patients in extremis such as: (1) hypoxemia requiring supplemental oxygen 100% FiO2,\n             (2) life threatening coagulopathy, or (3) deep coma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "6 Hours", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02071160", 
            "org_study_id": "01012012"
        }, 
        "intervention": {
            "arm_group_label": "Melatonin/ hypothermia group", 
            "description": "Melatonin is administered to the melatonin/hypothermia group (n=15)  in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment.  Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.", 
            "intervention_name": "Melatonin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Melatonin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIE", 
            "hypothermia", 
            "encephalopathy", 
            "anti oxidants", 
            "MRI"
        ], 
        "lastchanged_date": "February 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tanta", 
                    "country": "Egypt", 
                    "state": "Gharbeya"
                }, 
                "name": "Tanta University Children's Hospital"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "3", 
        "official_title": "Melatonin for Neuroprotection Following Perinatal Asphyxia", 
        "overall_official": {
            "affiliation": "Tanta University", 
            "last_name": "Heba Mahdy, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Egypt: Ministry of Higher Education", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Serum melatonin concentration (pg/ ml)", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }, 
            {
                "measure": "Plasma superoxide dismutase (SOD) activity (U/ml)", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }, 
            {
                "measure": "Serum nitric oxide (NO) concentrations (\u00b5mol/L)", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }
        ], 
        "reference": [
            {
                "PMID": "15168319", 
                "citation": "Gitto E, Reiter RJ, Cordaro SP, La Rosa M, Chiurazzi P, Trimarchi G, Gitto P, Calabr\u00f2 MP, Barberi I. Oxidative and inflammatory parameters in respiratory distress syndrome of preterm newborns: beneficial effects of melatonin. Am J Perinatol. 2004 May;21(4):209-16."
            }, 
            {
                "PMID": "14966737", 
                "citation": "Gitto E, Romeo C, Reiter RJ, Impellizzeri P, Pesce S, Basile M, Antonuccio P, Trimarchi G, Gentile C, Barberi I, Zuccarello B. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg. 2004 Feb;39(2):184-9; discussion 184-9."
            }, 
            {
                "PMID": "22370283", 
                "citation": "Chen YC, Tain YL, Sheen JM, Huang LT. Melatonin utility in neonates and children. J Formos Med Assoc. 2012 Feb;111(2):57-66. doi: 10.1016/j.jfma.2011.11.024. Epub 2012 Feb 15. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02071160"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tanta University", 
            "investigator_full_name": "Heba Mahdy", 
            "investigator_title": "Assistant Professor of Pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of EEG abnormalities", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Incidence of MRI abnormalities", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Incidence of abnormal neurological examination", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Incidence of abnormal  Denver Developmental Screening Test II", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Tanta University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tanta University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}